These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis. Ge G; Yang Z; Li D; Zhang N; Chen B; Shi D Front Immunol; 2022; 13():959740. PubMed ID: 35967437 [TBL] [Abstract][Full Text] [Related]
3. Analysis of pathogenic factors of Candida albicans and the effect of vaginal immunization on recurrent vulvovaginal candidiasis in mice. Shao MK; Qi WJ; Hou MY; Luo DD J Obstet Gynaecol Res; 2022 Mar; 48(3):857-865. PubMed ID: 34970814 [TBL] [Abstract][Full Text] [Related]
5. Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis. Moreira D; Ruiz LS; Leite-Jr DP; Auler ME; Ramos RTB; Costa VT; Lara BR; Gasparetto A; Gandra RF; Melhem MSC; Paula CR Mycopathologia; 2021 Jun; 186(3):411-421. PubMed ID: 34120275 [TBL] [Abstract][Full Text] [Related]
6. Virulence is one of the mechanisms of vulvovaginal candidiasis recurrence, rather than drug resistance. Li X; Chen S; Lyu X; Tian J Med Mycol; 2022 Nov; 60(11):. PubMed ID: 36328948 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. Vicariotto F; Del Piano M; Mogna L; Mogna G J Clin Gastroenterol; 2012 Oct; 46 Suppl():S73-80. PubMed ID: 22955364 [TBL] [Abstract][Full Text] [Related]
10. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. Phillips NA; Rocktashel M; Merjanian L Drug Des Devel Ther; 2023; 17():363-367. PubMed ID: 36785761 [TBL] [Abstract][Full Text] [Related]
11. Methods Related to the Immunopathogenesis of Vulvovaginal Candidiasis and Associated Neutrophil Anergy. Yano J; Fidel PL Methods Mol Biol; 2022; 2542():193-218. PubMed ID: 36008666 [TBL] [Abstract][Full Text] [Related]
16. Recurrent Vulvovaginal Candidiasis: An Immunological Perspective. Rosati D; Bruno M; Jaeger M; Ten Oever J; Netea MG Microorganisms; 2020 Jan; 8(2):. PubMed ID: 31972980 [TBL] [Abstract][Full Text] [Related]
17. The bacterial communities in vagina of different Candida species-associated vulvovaginal candidiasis. Chen Z; Jin J; Chen H; Chen Y; Feng S Microb Pathog; 2023 Apr; 177():106037. PubMed ID: 36842517 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates. Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724 [TBL] [Abstract][Full Text] [Related]
19. [Local humoral immunity in vulvovaginal candidiasis]. Amouri I; Hadrich I; Abbes S; Sellami H; Ayadi A Ann Biol Clin (Paris); 2013; 71(2):151-5. PubMed ID: 23587578 [TBL] [Abstract][Full Text] [Related]
20. The dynamic changes of vaginal microecosystem in patients with recurrent vulvovaginal candidiasis: a retrospective study of 800 patients. Yue XA; Chen P; Tang Y; Wu X; Hu Z Arch Gynecol Obstet; 2015 Dec; 292(6):1285-94. PubMed ID: 26041326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]